0.559
0.18%
-0.001
After Hours:
.559
Forte Biosciences Inc stock is currently priced at $0.559, with a 24-hour trading volume of 9,515.
It has seen a -0.18% decreased in the last 24 hours and a -17.79% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.57 pivot point. If it approaches the $0.55 support level, significant changes may occur.
Previous Close:
$0.56
Open:
$0.58
24h Volume:
9,515
Market Cap:
$20.37M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-0.4819
EPS:
-1.16
Net Cash Flow:
$-28.71M
1W Performance:
-4.13%
1M Performance:
-17.79%
6M Performance:
-19.10%
1Y Performance:
-45.73%
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
310 618 6994
Address
3060 Pegasus Park Drive, Building 6, Dallas, CA
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Sep-03-21 | Downgrade | Truist | Buy → Hold |
May-14-21 | Initiated | B. Riley Securities | Buy |
Mar-26-21 | Initiated | Citigroup | Buy |
Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Traders Buy Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO) - Defense World
Defense World
Alopecia Areata Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies by DelveInsight - openPR
openPR
Alopecia Areata Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies by DelveInsight - openPR
openPR
Forte Biosciences, Inc. Expected to Post FY2024 Earnings of ($0.66) Per Share (NASDAQ:FBRX) - Defense World
Defense World
Equities Analysts Issue Forecasts for EQB Inc.'s FY2024 Earnings (TSE:EQB) - Defense World
Defense World
Equities Analysts Set Expectations for Forte Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:FBRX) - Defense World
Defense World
Forte Biosciences Inc Stock (FBRX) Financials Data
Forte Biosciences Inc (FBRX) Net Income 2024
FBRX net income (TTM) was -$31.48 million for the quarter ending December 31, 2023, a -126.79% decrease year-over-year.
Forte Biosciences Inc (FBRX) Cash Flow 2024
FBRX recorded a free cash flow (TTM) of -$28.71 million for the quarter ending December 31, 2023, a -250.71% decrease year-over-year.
Forte Biosciences Inc (FBRX) Earnings per Share 2024
FBRX earnings per share (TTM) was -$1.04 for the quarter ending December 31, 2023, a -30.00% decline year-over-year.
Forte Biosciences Inc Stock (FBRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Wagner Paul A. | SEE REMARKS |
Apr 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,881,627 |
Riley Antony A | Chief Financial Officer |
Jan 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
192,285 |
Chen Hubert C | See remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
7,500 |
0 |
96,478 |
Wagner Paul A. | See Remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,854,486 |
Wagner Paul A. | See Remarks |
Dec 18 '23 |
Buy |
0.75 |
10,000 |
7,525 |
1,823,236 |
Wagner Paul A. | See Remarks |
Dec 14 '23 |
Buy |
0.72 |
10,000 |
7,200 |
1,813,236 |
Wagner Paul A. | See Remarks |
Dec 13 '23 |
Buy |
0.70 |
10,520 |
7,351 |
1,803,236 |
Wagner Paul A. | See Remarks |
Dec 12 '23 |
Buy |
0.65 |
4,776 |
3,088 |
1,792,716 |
Wagner Paul A. | See Remarks |
Dec 11 '23 |
Buy |
0.65 |
25,000 |
16,188 |
1,787,940 |
Wagner Paul A. | See Remarks |
Dec 08 '23 |
Buy |
0.62 |
15,000 |
9,300 |
1,762,940 |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Cap:
|
Volume (24h):